Kohzuki M, Kanazawa M, Liu P F, Kamimoto M, Yoshida K, Saito T, Yasujima M, Sato T, Abe K
Section of Internal Medicine & Disability Prevention, Disability Science, Tohoku University Graduate School of Medicine, Sendai, Japan.
J Hypertens. 1995 Dec;13(12 Pt 2):1785-90.
To assess the potential of the kallikrein-kinin and renin-angiotensin systems in mediating the cardio- and renoprotective effects of angiotensin converting enzyme (ACE) inhibitors in rats with chronic renal failure.
Spontaneously hypertensive rats (SHR) and normotensive control Wistar-Kyoto (WKY) rats subjected to five-sixths nephrectomy were randomly assigned to treatment with vehicle, a kinin antagonist (Hoe 140) or an ACE inhibitor (cilazapril) or both drugs, intraperitoneally via osmotic minipumps for 4 weeks. In addition, the effects of a chronic infusion of a specific angiotensin receptor antagonist (losartan) alone or in combination with an ACE inhibitor (enalapril) were also investigated in nephrectomized SHR for 2 weeks.
In nephrectomized SHR and WKY rats, cilazapril alone significantly reduced systolic blood pressure, urinary protein excretion, heart weight and serum creatinine. In nephrectomized SHR, Hoe 140 alone or cilazapril in combination with Hoe 140 (7 or 70 mu g/kg per day) induced no changes in these parameters, other than those associated with the effects of cilazapril alone. In nephrectomized WKY rats, cilazapril in combination with Hoe 140 (70 mu g/kg per day) slightly, but not significantly, attenuated the antihypertensive effect of cilazapril but did not affect the other parameters. These results were confirmed by morphological analysis of kidneys. All the drug regimens provided effective protection against an increase in focal glomerular sclerosis. Enalapril did not modify the antihypertensive and renoprotective effects of losartan in nephrectomized SHR.
The present results indicate that the kallikrein-kinin system might not be a major factor in the cardio- and renoprotective effects of ACE inhibitors in rats with chronic renal failure.
评估激肽释放酶-激肽系统和肾素-血管紧张素系统在介导血管紧张素转换酶(ACE)抑制剂对慢性肾衰竭大鼠心脏和肾脏保护作用中的潜力。
将接受六分之五肾切除的自发性高血压大鼠(SHR)和血压正常的对照Wistar-Kyoto(WKY)大鼠随机分为几组,通过渗透微型泵腹腔内给予溶媒、激肽拮抗剂(Hoe 140)或ACE抑制剂(西拉普利)或两种药物,持续4周。此外,还在肾切除的SHR中研究了单独慢性输注特异性血管紧张素受体拮抗剂(氯沙坦)或与ACE抑制剂(依那普利)联合使用2周的效果。
在肾切除的SHR和WKY大鼠中,单独使用西拉普利可显著降低收缩压、尿蛋白排泄、心脏重量和血清肌酐。在肾切除的SHR中,单独使用Hoe 140或西拉普利与Hoe 140联合使用(每天7或70μg/kg)除了西拉普利单独作用的效果外,这些参数没有变化。在肾切除的WKY大鼠中,西拉普利与Hoe 140联合使用(每天70μg/kg)轻微但不显著地减弱了西拉普利的降压作用,但不影响其他参数。肾脏的形态学分析证实了这些结果。所有药物方案均有效预防了局灶性肾小球硬化的增加。依那普利并未改变氯沙坦对肾切除SHR的降压和肾脏保护作用。
目前的结果表明,激肽释放酶-激肽系统可能不是ACE抑制剂对慢性肾衰竭大鼠心脏和肾脏保护作用的主要因素。